- Home
- NXTC vs SMSI Comparison
NXTC vs SMSI Comparison
Compare NXTC & SMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- SMSI
- Stock Information
- Founded
- NXTC 2015
- SMSI 1982
- Country
- NXTC United States
- SMSI United States
- Employees
- NXTC N/A
- SMSI N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- SMSI Computer Software: Prepackaged Software
- Sector
- NXTC Health Care
- SMSI Technology
- Exchange
- NXTC Nasdaq
- SMSI Nasdaq
- Market Cap
- NXTC 13.0M
- SMSI 15.3M
- IPO Year
- NXTC 2019
- SMSI 1995
- Fundamental
- Price
- NXTC $5.76
- SMSI $0.71
- Analyst Decision
- NXTC Strong Buy
- SMSI Strong Buy
- Analyst Count
- NXTC 2
- SMSI 1
- Target Price
- NXTC $25.50
- SMSI $5.00
- AVG Volume (30 Days)
- NXTC 16.7K
- SMSI 110.5K
- Earning Date
- NXTC 11-06-2025
- SMSI 11-12-2025
- Dividend Yield
- NXTC N/A
- SMSI N/A
- EPS Growth
- NXTC N/A
- SMSI N/A
- EPS
- NXTC N/A
- SMSI N/A
- Revenue
- NXTC N/A
- SMSI $18,658,000.00
- Revenue This Year
- NXTC N/A
- SMSI $0.03
- Revenue Next Year
- NXTC N/A
- SMSI $52.29
- P/E Ratio
- NXTC N/A
- SMSI N/A
- Revenue Growth
- NXTC N/A
- SMSI N/A
- 52 Week Low
- NXTC $2.69
- SMSI $0.52
- 52 Week High
- NXTC $19.20
- SMSI $1.95
- Technical
- Relative Strength Index (RSI)
- NXTC 66.21
- SMSI 45.28
- Support Level
- NXTC $5.19
- SMSI $0.71
- Resistance Level
- NXTC $5.15
- SMSI $0.76
- Average True Range (ATR)
- NXTC 0.27
- SMSI 0.03
- MACD
- NXTC 0.08
- SMSI 0.00
- Stochastic Oscillator
- NXTC 89.05
- SMSI 19.25
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.